NCT07596823 Hematological Indices and Sympathetic Block Response in Neuropathic Pain
| NCT ID | NCT07596823 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ankara City Hospital Bilkent |
| Condition | Neuropathic Pain |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2026-06-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective observational study aims to evaluate the relationship between hematological inflammatory indices and clinical treatment response in patients with neuropathic pain undergoing sympathetic nerve block procedures as part of routine clinical care. Hematological parameters including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), aggregate index of systemic inflammation (AISI), and red cell distribution width (RDW) will be evaluated before and after treatment. The association between changes in these indices and pain outcomes will be analyzed.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Diagnosis of neuropathic pain based on clinical evaluation * DN4 and/or LANSS scores compatible with neuropathic pain * Undergoing sympathetic nerve block as part of routine clinical treatment * Availability of pre-treatment and follow-up hemogram parameters * Ability to provide written informed consent Exclusion Criteria: * Age \<18 years * Active infection or acute inflammatory disease * Active malignancy * History of hematological disease * Immunosuppressive therapy or systemic corticosteroid use * Major surgery or severe trauma within the last month * Pregnancy or breastfeeding * Autoimmune or rheumatologic inflammatory disease * Missing follow-up data
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07596823 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neuropathic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07596823 currently recruiting?
Yes, NCT07596823 is actively recruiting participants. Contact the research team at sabuncuulku@gmail.com for enrollment information.
Where is the NCT07596823 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT07596823 clinical trial?
NCT07596823 is sponsored by Ankara City Hospital Bilkent. The trial plans to enroll 120 participants.